Malignant hyperthermia;Maligne hyperthermie

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 35, Issue 3, 2000, Pages 147-172

  Steinfath, M ^a   Wappler, F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GERMANY; HEREDITY; HUMAN; MALIGNANT HYPERTHERMIA; PATHOPHYSIOLOGY; REVIEW;

EID: 0034107172     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-12158     Document Type: Review

References (188)

1. Adnet PJ, Krivosic-Horber RM, Krivosic I: Viability criterion of muscle bundles used in the in vitro contracture test in patients with neuromuscular diseases. Br. J. Anaesth. 1974:72:93-97
2. Artru AA, Gronert GA: Cerebral metabolism during porcine malignant hyperthermia. Anesthesiology. 1980;53:121-126
3. Bach MA, Blum DM, Rose SR, Charnas LR: Myalgia and elevated creatine kinase activity associated with subcutaneous infections of diluent. J. Pediat. 1992;121:650-651
4. Ball SP, Johnson KJ: The genetics of malignant hyperthermia. J. Med. Genet. 1993;30:89-93
5. 2 monitoring. Its use in the diagnosis and management of malignant hyperthermia. Anaesthesia. 1984;39:1000-1003
6. Berkowitz A, Rosenberg H: Femoral nerve block with mepivacaine for muscle biopsy in malignant hyperthermia patients. Anesthesiology. 1985;62:651-652
7. Berman MC, Harrison GG, Dutoit P, Bull JE, Keuch JE: Halothane-induced hyperpyrexia in landrace pigs. S. Afr. Med. J. 1969;43:545
8. Berridge MJ: Inositol trisphosphate and calcium signalling. Nature. 1993;361:315-325
9. Böhm M, Roewer N, Schmitz W, Scholz H, Schulte am Esch J: Effects of beta- and alpha-adrenergic agonists, adenosine and carbachol on heart muscle isolated from malignant hyperthermia susceptible swine. Anesthesiology. 1988;68:38-43
10. Brewer GE: Heat-stroke as a post-operative complication. J. Am. Med. Assoc. 1900;35:1685
11. Britt BA: Malignant hyperthermia: A review: In: Pyretics and antipyretics. Milton AS (Hrsg.) Springer, Berlin-Heidelberg-New York (Handbook of experimental pharmacology, Vol LX) 1982:547-615
12. Britt GA: Combined anesthetic- and stress-induced malignant hyperthermia in two offspring of malignant hyperthermic-susceptible parents. Anesth, Analg. 1988;67:393-399
13. Britt BA: Heriditary and epidemiological aspects of malignant hyperthermia. In: Malignant hyperthermia. Nalda Felipe MA, Gottmann S, Khambatta HJ (Hrsg.) Current concepts. Normed, Englewood 1989:19-39
14. Britt BA, Endrenyi L, Peters PL, Kwong FHF, Kadijevic L: Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations. Can. Anaesth. Soc. J. 1976;23:262-284
15. Britt BA, Scott EA: Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia. Anesth. Analg. 1986;65:171-175
16. Brownell KW: Malignant hyperthermia: relationship to other diseases. Br. J. Anaesth. 1988; 60:303-308
17. Campbell IT, Ellis FR, Evans RT: Metabolic rate and blood hormone and metabolic levels of individuals susceptible to malignant hyperpyrexia at rest and in response to food and mild exercise. Anesthesiology. 1981;55:46-52
18. Campbell IT, Ellis FR, Evans RE, Mortimer MG: Studies of body temperatures, blood lactate, cortisol and free fatty acid levels during exercise in human subjects susceptible to malignant hyperpyrexia. Acta. Anaesthesiol. Scand. 1983;27:349-355
19. Carr AS, Lerman J, Cunliffe M, McLeod ME, Britt BA: Incidence of malignant hyperthermia reactions in 2214 patients undergoing muscle biopsy. Can. J. Anaesth. 1995;44:281-286
20. Carroll JB, Katholnigg D: Increased incidence of masseter spasm in children with strabismus anesthetized with halothane and succinylcholine. Anesthesiology. 1987;67:559-561
21. Censier K, Urwyler A, Zozato F, Treves S: Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. J. Clin. Invest. 1998;101:1233-1242
22. Cho E, Marx GF: Anaesthesia in a patient with osteogenesis imperfecta. Br. J. Anaesth. 1992; 62:422-423
23. Denborough MA: Malignant hyperpyrexia. Med. J. Aust. 1977;2:757-758
24. Denborough MA, Dennett X, Dennett X, Anderson RM: Central core disease and malignant hyperpyrexia. Br. Med. J. 1973;1:272-273
25. Denborough MA, Hopkinson KC, O'Brien RO, Foster PS: Overheating alone can trigger malignant hyperthermia in piglets. Anaesth. Intens. Care. 1996;24:348-354
26. Denborough MA, Lovell RRH: Anaesthetic deaths in a family. Lancet. 1960;II:45
27. Deshwitz M, Sreter FA: Azumolene reverses episodes of malignant hyperthermia in susceptible swine. Anesth. Analg. 1990;70:253-255
28. Deufel T, Golla A, Iles D, Meindl A, Meitinger T, Schindelhauer D, DeVries A, Pongartz D, MacLennan DH, Johnson KJ, Lehmann-Horn F: Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am. J. Hum. Genet. 1992;50:1151-1161
29. Deufel T, Sudbrak R, Feist Y, Rübsam B, Du Chesne I, Schäfer KL, Roewer N, Grimm T, Lehmann-Horn F, Hartung EJ, Müller CR: Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotype and haplotypes for the MHSI region on chromosome 19q12-13.2, comprising the C1840T transition in the RYRI gene. Am. J. Hum. Genet. 1995;56:1334-1342
30. Ducart A, Adnet P, Renaud B, Riou B, Krivosic-Horber R: Malignant hyperthermia during sevoflurane administration. Anesth. Analg. 1995;80:609-611
31. Eberlein HJ: Therapie der malignen Hyperthermie. Vorläufige Mitteilung. Anaesthesia. 1979;28:247-248
32. Ellis FR, Harriman DGH, Keaney NP, Kyei-Mensah K, Tyrell JH: Halothane-induced muscle contracture as a cause of hyperpyrexia. Br. J. Anaesth. 1971;43:721-722
33. Eng GD, Becker MJ, Muldoon SM: Electrodiagnostic tests in the detection of malignant hyperthermia. Muscle Nerve. 1984;7:618-625
34. European Malignant Hyperthermia Group: A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br. J. Anaesth. 1984;56:1267-1269
35. Fagerlund T, Islander G, Ranklev E, Harbitz I, Hauge JG, Mokleby E, Berg K: Genetic recombination between malignant hyperthermia and calcium release channel in skeletal muscle. Cin. Genet. 1992;41:270-272
36. Fill M, Coronado R, Mickelson JR, Vilven J, Ma JJ, Jacobson BA, Louis CF: Abnormal ryanodine receptor channels in malignant hyperthermia. Biophys. J. 1990;57:471-475
37. Fill M, Stefani E, Nelson TE: Abnormal human sarcoplasmic reticulum Ca + + release channels in malignant hyperthermic skeletal muscle. Biophys. J. 1991;59:1085-1090
38. Fletscher JE, Rosenberg H, Lizzo FH: Effects od droperidol, haloperidol and ketamine on halothane, succinylcholine and caffeine contractures: implications for malignant hyperthermia. Acta. Anaesthesiol. Scand. 1989;33:187-192
39. Fletscher JE, Tripolitis L, Hubert M, Hubert M, Vita GM, Levitt RC, Rosenberg H: Genotype and phenotype relationship for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia. Br. J. Anaesth. 1995;75:307-310
40. Foster PS, Gesini E, Denborough MA: Inositol 1,4,5-trisphosphate metabolism in red blood cells from individuals susceptible to malignant hyperpyrexia. Lancet. 1993;342:986-987
41. Foster PS, Gesini E, Glaudianos C, Hopkinson KC, Denborough MA: Inositol 1,4,5-trisphosphate phosphatase deficiency and malignant hyperthermia in swine. Lancet. 1989;II:124-127
42. Frank JP, Harati Y, Butler J, Nelson TE, Scott CI: Central core disease and malignant hyperthermia syndrome. Ann. Neuro. 1980;117:11-17
43. Fu FS, Scharf JE, Mangar D, Miller WD: Malignant hyperthermia involving the adminstration of desflurane. Can. J. Anaesth. 1996;43:687-690
44. Fujii J, Otsu K, Zorzato F, De Leon S, Khanna VK, Weiler JE, O'Brien J, MacLennan DD: Identification of a mutation in porcine ryanodine receptor associated with malignant hyerthermia. Science. 1991;253:448-451
45. Galloway GJ, Denborough MA: Suxamethonium chloride and malignant hyperthermia. Br. J. Anaesth. 1986;58:447-450
46. Gerdes C, Richter A, Annies R, Löscher W: Increase of serotonin in plasma during onset of halothane-induced malignant hyperthermia in pigs. Eur. J. Pharmacol. 1992;220:91-94
47. Gibson CL: Heat-stroke as a post-operative complication. J. Am. Med. Assoc. 1900;35:1685
48. Gibson CL, Tuttle JJ: Heat stroke as a post-operative complication. Med News (NY) 1900; 77:883-884
49. Gillard EF, Otsu K, Fujii J, Duff C, De Leon S, Khanna VK, Britt BA, Mac Lennan DH: Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RyR1) gene in individuals with malignant hyperthermia. Genomics. 1992;13: 1247-1254
50. Gillard EF, Otsu K, Khanna VK, Le Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH: A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics. 1991;11:751-755
51. 2, calcium, digoxin, and potassium on cardiac and skeletal muscle metabolism in malignant hyperthermia susceptible swine. Anesthesiology 1986;64:24-28
52. Gronert GA, Antognini JF: Malignant hyperthermia. In: Anesthesia. Miller RD (Ed.), Churchill Livingstone, New York 1994;4. Edition:1075-1093
53. Gronert GA, Milde JH, Theye RW: Role of sympathetic activity in porcine malignant hyperthermia. Anesthesiology. 1977;47:411-415
54. Gronert GA, Thompson RL, Onofrio B: Human malignant hyperthermia: awake episodes and correction by dantrolene. Anesth. Analg. 1980;59:377-378
55. Gronert GA, White DA: Failure of norepinephrine to initiate porcine malignant hyperthermia. Eur. J. Physiol. 1988;411:226-228
56. Hackl W, Winkler M, Mauritz W, Sporn P, Steinbereithner K: Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Br. J. Anaesth. 1991;66:138-140
57. Hackl W, Winkler M, Mauritz W, Steinbereithner K: Die Wirkung von Ketamin auf das muskuläre Kontraktionsverhalten. Anaesthesist. 1989;38:681-686
58. Hall LW, Woolf N, Bradley JWP, Jolly DW: Unusual reaction to suxamethonium chloride. Br. Med. J. 1966;II:1305
59. Harbitz I, Cholldhary B, Thomsen PD, Davies W, Kaufmann U, Kran S, Gustanvsson I, Christensen K: Hyperthermia locus, to the 6p11-qq21 segment of chromosome 6. Genomics 1990;8:243-248
60. Harriman DGF: Malignant hyperthermia myopathy - a critical review. Br. J. Anaesth. 1988;60:309-316
61. Harrison GG: Control of malignant hyperpyrexia syndrome in MHS swine by dantrolene sodium. Br. J. Anaesth. 1975;47:62-65
62. Harrison GG: Dantrolene - dynamics and kinetics. Br. J. Anaesth. 1988;60:279-286
63. Harrison GG, Verburg C: Erythrocyte osmotic fragility in hyperthermia-susceptible swine. Br. J. Anaesth. 1973;45:131-133
64. Hartung E, Horbaschek H, Olthoff D, Deutrich C, Lehmann-Horn F, Baur Ch, Tegazzin V, Doetsch S, Quasthoff S, Hofmann M, Schwefler B, Jantzen JP, Wappler F, Scholtz J: Die regionale Verbreitung der Maligne-Hyperthermie-Veranlagung in Deutschland: Stand 1997. Anaesthesiol. Intensivmed. Notfallmed. Schmerzther. 1998;33:238-243
65. Hartung E, Koob M, Anetseder M: Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and ryanodine-contracture-test results in MH susceptible, normal and control muscle. Acta Anaesthesiol. Scand. 1996;40:437-444
66. Heiman-Patterson TD, Martino C, Rosenberg HR, Fletscher JE, Tahmoush AJ: Malignant hyperthermia in myotonia congenita. Neurology 1988;38:810-812
67. Heiman-Patterson TD, Rosenberg HR, Binning CPS, Tahmoush AJ: King-Denborough syndrome: Contracture testing and literature review. Pediatr Neurol. 1986;2:175-177
68. Herrmann-Frank A, Richter M, Lehmann-Horn F: 4-chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem. Pharmacol. 1996;52:149-155
69. Hermesh H, Aizenberg D, Lapidot M, Munitz H: Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am. J. Psychiatry. 1988;145:1431-1434
70. Heytens L, de Cauwer H, Frank A: Central/minicore disease or histological pattern, and MH susceptibility. Proceedings Annual Meeting Eur MH Group. 1997:12
71. Heytens L, Martin JJ, van de Keift E, Bossaert LL: In vitro contracture tests in patients with various neuromuscular diseases. Br. J. Anaesth. 1992;68:72-75
72. Hopkins PM, Ellis FR, Halsall PJ: Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br. J. Anaesth. 1991;66:611-613
73. Hopkins PM, Ellis FR, Halsall PJ, Stewart AD: Analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia. Anesth. Analg. 1997;84:648-656
74. Houde A, Pommier SA, Roy R: Detection of the ryanodine receptor mutation associated with malignant hyperthermia in purebred swine populations. J. Anim. Sci. 1993;71:1414-1418
75. Iaizzo PA, Kehler CH, Carr RJ, Sessler DI, Belani KG: Prior hypothermia attenuates malignant hyperthermia in susceptible swine. Anesth. Analg. 1996;82:803-809
76. Iaizzo PA, Seewald MJ, Olsen R: Enhanced mobilization of intracellular calcium induced by halothane in hepatocytes isolated from swine susceptible to malignant hyperthermia. Anesthesiology. 1991;74:531-538
77. Iaizzo PA, Johnson BA, Nagao K, Gallagher WJ: WJ. 4-chloro-m-cresol triggers malignant hyperthermia in susceptible swine at doses greatly exceeding those found in drug preparations. Anesthesiology. 1999;90:1723-1732
78. Iles DE, Lehmann-Horn F, Scherer SW, Tsui L-C, Olde Weghuis D, Suijkerbuijk RF, Heytens L, Grimm T: Localisation of the gene encoding the alpha2/delta-subunits of the L-type voltage dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum. Mol. Genet. 1994;3:969-975
79. Iles DE, Segers B, Heytens L, Sengers RCA, Wieringa B: High-resolution physical mapping of four microsatellite repeat markers near the RYR1 locus on chromosome 19q13.1 and apparent exclusion of the MHS locus from this region in two malignant hyperthermia susceptible families. Genomics. 1992;14:749-754
80. Iles DE, Segers B, Sengers RCA, Monsieurs K, Heytens L, Halsall PJ, Hopkins PM, Ellis FR, Hall-Curran JL, Steweart AD, Wieringa B: Genetic mapping of the β1- and gamma-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility. Hum. Mol. Genet. 1993;2:863-868
81. Isaacs H, Badenhorst M: Dominantly inherited malignant hyperthermia (MH) in the King-Denborough syndrome. Muscle Nerve. 1992;15:740-742
82. Isaacs H, Badenhorst M: False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology. 1993;79:5-9
83. Johnson K: Malignant hyperthermia hots up! Hum. Mol. Genet. 1993;2:849
84. Kalow W, Britt BA, Terrau ME, Haist C: Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970;11:895-898
85. Karan SM, Lojeski EW, Haynes DH: Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. Anesth. Analg. 1996;82:796-802
86. Keating KE, Quane KA, Manning BM, Lehane M, Hartung E, Censier K, Urwyler A, Klausnitzer M, Muller CR, Heffron JJA, McCarthy TV: Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum. Mol. Genet. 1994;3:1855-1858
87. Kim DH, Sreter FA, Ohnishi ST, Ryan JF, Roberts J, Allen PD, Meszaros LG, Antoniu B, Ikemoto N: Kinetic studies of calcium release from sarcoplasmic reticulum of normal and MHS pig muscle. Biochim. Biophys. Acta. 1984;175:320-327
88. Klip A, Elliott ME, Frodis W, Britt BA, Pegg W, Scott E: Anaesthetic-induced increase in ionised calcium in blood mononuclear cells from malignant hyperthermia susceptible patients. Lancet. 1987;11:463-466
89. Klip A, Mills GB, Britt BA, Elliott ME: Halothane-dependent release of intracellular calcium in blood cells in malignant hyperthermia. Am. J. Physiol. 1990;258:C495-C503
90. Kochs E, Hoffman WE, Roewer N, Schulte am Esch J: Alterations in brain electrical activity may indicate the onset of malignant hyperthermia in swine. Anesthesiology. 1990;73:1236-1242
91. Kochs E, Hoffman WE, Schulte am Esch J: Improvement of brain electrical activity during treatment of porcine malignant hyperthermia with dantrolene. Br. J. Anaesth. 1993;71:881-884
92. Köchling A, Wappler F, Scholz J, Steinfath M, Roewer N: Fulminant malignant hyperthermia during first manifestation of ketoacidotic diabetic coma. Proceedings Annual Meeting Eur MH Group 1995:60
93. Krivosic-Horber R, Adnet P, Reyford , Krivosic I: Problems in malignant hyperthermia epidemiology. Proceedings Annual Meeting Eur MH Group 1995:8-15
94. Lai FA, Erickson HP, Rousseau E, Liu QY, Meissner G: Purification and reconstitution of the calcium release channel from skeletal muscle. Nature. 1988;331:315-319
95. Larach MG, Localio AR, Alleen GC: A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771-779
96. Lehmann-Horn F, Iaizzo PA: Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia? Br. J. Anaesth. 1990;65:692-697
97. Lehmann-Horn F, Klein W, Spittelmeister W: Neurologisch relevante Aspekte der malignen Hyperthermie. Aktuelle Neurologie. 1991;18:117-123
98. Levitt RC, Nouri N, Jedlicka AE, McKusick VA, Marks AR, Shutack JG, Fletcher JE, Rosenberg H, Meyers DA: Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics. 1991;11:543-547
99. Levitt RC, Olckers A, Meyers S, Fletcher JE, Rosenberg H, Isaacs H, Meyers DA: Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics. 1992;14:562-566
100. Lister D, Hall GM, Lucke JN: Malignant hyperthermia: a human and porcine stress syndrome? Lancet. 1975;II:519
101. Löscher W, Witte U, Fredow G, Ganter M, Bickhardt K: Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia. Naunyn-Schmiedeberg's Arch. Pharmacol. 1990;34:483-493
102. Lopez JR, Alamo L, Caputo C, Wikinski J, Ledezma D: Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve. 1985;8:355-358
103. Lynch PJ, Krivosic-Horber R, Reyford H, Monnier N, Quane K, Adnet P, Haudecoeur G, Krivosic I, McCarthy T, Lunardi J: Identification of heterozygous and honozygous individuals with the novel RYR1 mutation cys35arg in a large kindred. Anesthesiology. 1997;86:620-626
104. Maccani RM, Wedel DJ, Hofer RE: Norepinephrine does not potentiate porcine malignant hyperthermia. Anesth. Analg. 1996;82:790-795
105. MacLennan DH, Duff C, Zorzato F, Fujii J, Philips M, Morneluk RG, Frodis W, Britt BA, Worton RG: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 1990;343:559-561
106. MacLennan DH, Philips MS: Malignant hyperthermia. Science. 1992;256:789-794
107. Mauritz W, Sporn P, Steinbreitner K: Maligne Hyperthermie in Österreich, I. Epidemiology und Klinik. Anaesthesist. 1986;5:639-650
108. McCarthy TV: Developments in the genetics of MH. Proceedings of the Annnual Meeting of the European Malignant Hyperthermia Group 1995:88-98
109. McCarthy TV, Healy JMS, Heffron JJA, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K: Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 1990;343:562-564
110. McCarthy TV, Quane KA, Ording H: Genotype - phenotype correlation of mutations in the ryanodine receptor (RYR1) with the malignant hyperthermia IVCT. Proceedings Annual Meeting Eur MH Group 1997:44
111. Meier-Hellmann A, Römer M, Hannemann L, Kersting T, Reinhart K: Früherkennung einer malignen Hyperthermie durch Capnometrie. Anaesthesist. 1990;39:41-43
112. Meissner G: Adenine nucleotide stimulation of Ca + + - induced Ca + + -release in sarcoplasmic reticulum. J. Biol. Chem. 1984;229:2365-2374
113. Meissner G: Ryanodine receptor/Ca + + -release channel and their regulation by endogenous effectors. Annu. Rev. Physiol. 1994;56:485-508
114. Mezin P, Payen JF, Bosson JL, Bramilla E, Stieglitz P: Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Br. J. Anaesth. 1997;79:327-331
115. Michalek-Sauberer A, Fricker R, Gradwohl I, Gilly H: A case of suspected malignant hyperthermia during desflurane administration. Anesth. Analg. 1997;85:461-462
116. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF: Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J. Biol. Chem. 1988;263:9310-9315
117. Mickelson JR, Ross JA, Reed BK, Louis CF: Enhanced Ca + + induced calcium release by isolated sarcoplasmic reticulum vesicles from malignant hyperthermia susceptible pig muscle. Biochim. Biophys. Acta. 1986;862:318-328
118. Mignery GA, Südhof TC, Takai K, Camilli PD: Putative receptor for inositol 1,4,5-trisphosphate similar to ryanodine receptor. Nature. 1989;342:192-195
119. von Moschcowitz A: Postoperative heatstroke. Surg. Gynecol. Obstet. 1916;23:443-451
120. Nelson TE: Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. J. Clin. Invest. 1983;72:862-872
121. Ombrédanne L: De l'influence del' anesthesique-employe dans la genese chez les nourrissons. Rev. Med. Fr. 1929;10:617
122. Ogletree JW, Antognini JF, Gronert GA: Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. Am. J. Sports. Med. 1996;24:49-51
123. Ohnishi ST, Katagi H, Ohnishi T, Brownell AKW: Detection of malignant hyperthermia susceptibility using a spin label technique in red blood cells. Br. J. Anaesth. 1988;61:565-568
124. Olgin J, Rosenberg H, Allen G, Seestedt R, Chance B: A blinded comparision of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility. Anesth. Analg. 1971;72:36-47
125. Ooms L, Awouters F, Degryse F, Jageneau T: Ryanodine receptor/Ca + + -release channel and their regulation by endogenous effectors. Serotonin and S2 antagonists in veterinary. In: Veterinary pharmacology and toxicology. Ruckebusch Y, Toutain PL, Koritz GD (Hrsg.) MTP Press, Boston The Hague Dordrecht. 1983:263-281
126. Ording H: Incidence of malignant hyperthermia in Denmark. Anesth. Analg. 1985:64:700-704
127. Ordning H: Diagnosis of susceptibility to malignant hyperthermia in man. Br. J. Anaesth. 1988;60:287-302
128. Ordning H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJA, Heytens L, Kozac-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta. Anaesthesiol. Scand. 1997;41:955-966
129. Ording H, Hedengran AM, Skovgaard LT: Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta. Anaesthesiol. Scand. 1991;35:711-716
130. Otsu K, Khanna VK, Archibald AL, MacLennan DH: Cosegregation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine receptor gene in backcross families. Genomics. 1991;11:744-750
131. Otsu K, Willard HF, Khanna VK, Zorzato F, Green NM, MacLennan DH: Molecular cloning of cDNA encoding the Ca + + -release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J. Biol. Chem. 1990;265:13472-13483
132. Otsuka H, Komura Y, Mayumi T, Yamamura T, Kemmotsu O, Mukaida K: Malignant hyperthermia during sevoflurane anesthesia in a child with central core disease. Anesthesiology. 1991;75:699-701
133. Parness J, Palnitkar SS: Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 1995;270:18465-18472
134. Pessah IN, Lynch C, Gronert GA: Complex pharmacology of malignant hyperthermia. Anesthesiology. 1996;84:1275-1279
135. Phillips MS, Khanna VK, De Leon S, Frodis W, Britt BA, MacLennan DH: The substitution of Arg for Gly 2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia. Hum. Mol. Genet. 1994;3:2181-2186
136. Poels PJE, Joosten EMG, Sengers RCA, Stadhouders AM, Veerkamp JH, Benders AAGM: In vitro contraction test for malignant hyperthermia in patients with unexplained recurrent rhabdomyolysis. J. Neurolog. Sci. 1991;105:67-72
137. Porsberg P, Astrup G, Bendixen D, Lund AM, Ording H: Osteogenesis imperfecta and malignant hyperthermia. Anaesthesia. 1996;51:863-865
138. Püschel K, Koops E, Schulz-Baldes JG: Postoperative maligne Hyperthermie bei einem 7 Tage alten Säugling? Anaesthesist. 1989;38:81-84
139. Quane KA, Healy JMS, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ording H, Bendixen D, Mortier W, Linz U, Müller CR, McCarthy TV: Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genet. 1993;5:51-55
140. Quane KA, Keating KE, Healy JMS, Manning BM, Krivosic-Horber R, Krivosic I, Monnier N, Lunardi J, McCarthy TV: Mutation screening of the RYR1 gene in malignant hyperthermia: Detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics. 1994a;23:236-239
141. Quane KA, Keating KE, Manning BM, Healy JMS, Monsieurs K, Heffron JJA, Lehane M, Heytens L, Krivosic-Horber R, Adnet P, Ellis FR, Monnier N, Lunardi J, McCarthy TV: Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum. Mol. Genet. 1994b;3:471-476
142. Quane KA, Ording H, Keating KE, Manning BM, Heine R, Bendixen D, Berg K, Krivosic-Horber R, Lehmann-Horn F, Fagerlund T, McCarthy TV: Detection of a novel mutation at amino acid position 614 in the ryanodine receptor in malignant hyperthermia. Br. J. Anaesth. 1997;79:332-337
143. Reber A, Schumacher P, Urwyler A: Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Anaesthesia. 1993;48:862-865
144. von Richthofen V, Wappler F, Scholz J, Fiege M, Schulte am Esch J: Evaluierung von Maligne Hyperthermie-Episoden mit der Clinical Grading Scale. Anaesthesiol. Intensivmed. Notfallmed. Schmerzther. 1998;33:244-249
145. Roewer N: Maligne Hyperthermie heute. Anaesth. Intensivmed. Notfallmed. Schmerzther. 1991;26:431-449
146. Roewer N: Herz und Kreislauf bei maligner Hyperthermie. Anaesthesiologie und Intensivmedizin. Springer. 1992;221:1-247
147. Roewer N, Dziadzka A, Greim C, Kraas E, Schulte am Esch J: Cardiovascular and metabolic responses to anesthetic-induced malignant hyperthermia in swine. Anesthesiology. 1995;83:141-159
148. Ronjat M: Excitation-contraction coupling in skeletal muscle: recent advances in the identification of new actors. Proceedings of the Annual Meeting of the European Malignant Hyperthermia Group. 1995:46-51
149. Rosenberg H, Fletcher JE: An update on the malignant hyperthermia syndrome. Ann. Acad. Med. Singapore. 1994;23:84-97
150. Rubin SA, Zablocki AD: Hyperkalemia, verapamil, and dantrolene. Anesthesiology. 1987;66:246-249
151. Rübsam B, Seufert K, Preis I, Engelhardt W, Grimm T, Müller CR, Kress W, Hartung E: Maligne Hyperthermie: Familien ohne genetische Kopplung mit dem Ryanodinrezeptor. Anaesthesist. 1993;66:722-723
152. Rutberg H, Hakanson E, Hall GM, Jorfeldt L: Effects of graded exercise on leg exchange of energy substrates in malignant hyperthermia susceptible subjects. Anesthesiology. 1987;67:308-313
153. Ryan CA, Al-Ghamdi AS, Gayle M, Finer NN: Osteogenesis imperfecta and hyperthermia. Anesth. Analg. 1989;68:811-814
154. Scholz J, Roewer N, Rum U, Schmitz W, Scholz H, Schulte am Esch J: Possible involement of inositol-lipid metabolism in malignant hyperthermia. Br. J. Anaesth. 1991;66:692-696
155. Scholz J, Steinfath M, Roewer N, Patten M, Troll U, Schmitz E, Scholz H, Schulte am Esch J: Biochemical changes in malignant hyperthermia susceptible swine: cyclic AMP, inositol phosphates, alpha1-, beta1- and beta2-adrenoceptors in skeletal and cardiac muscle. Acta. Anaesthesiol. Scand. 1993;37:575-583
156. Scholz J, Troll U, Schulte am Esch J, Hartung E, Patten M, Sandig P, Schmitz W: Inositol-1,4,5-trisphosphate and malignant hyperthermia. Lancet. 1991;337:1361
157. Sethna NF, Rockoff MA, Worthen HM, Rosnow JM: Anesthesia-related complication in children with Duchenne muscular dystrophy. Anesthesiology. 1988;68:462-465
158. Shalev A, Munitz H: The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatry. Scand. 1986;73:337-347
159. Shulman M, Braverman B, Ivankovich AD, Gronert G: Sevoflurane triggers malignant hyperthermia in swine. Anesthesiology. 1981;54:259-260
160. Snyder HR, Davis CS, Bickerton RK, Halliday C: 1-((5-Arylfufurylidine)amino)hydantoins. A new class of muscle relaxants. J. Med. Chem. 1967;10:807-810
161. Sold M, Tschöp M, Sörensen N: Symptome der akuten Einklemmung nach Narkoseeinleitung bei Hydrocephalus - in Wahrheit eine maligne Hyperthermie. Anaesthesist. 1986;35:634-638
162. Solomons CC, Masson NC: Platelet model for halothane-induced effects on nucleotide metabolism applied to malignant hyperthermia. Acta Anaesthesiol. Scand. 1984;28:185-190
163. Spieß-Kiefer C: MH-verwandte Krankheitsbilder. In: Malignant Hyperthermia. Mauritz W, Bergmann H, Steinbereithner K (Hrsg,), 1. Auflage., Maudrich Wien-München-Bern 1989:97-103
164. Steinfalh M, Scholz J, Singh S, Wappler F: Welche Bedeutung haben Genotypveränderungen in der Diagnostik der malignen Hyperthermia? Anaesthesiol. Intensivmed. Notfallmed. Schmerzther. 1996;31:334-343
165. Steinfath M, Scholz J, Buxmann I, Wappler F, Schulte am Esch J: Spontaneous C1840-T mutation in the RYR 1 gene in a malignant hyperthermia susceptible family. Anesthesiology. 1997:87 (Suppl.):A339
166. Steinfath M, Scholz J, Buxmann I, Wappler F, Schulte am Esch J: Dantrolene and ryanodine binding sites are distinct and both are located at the sarcoplasmic reticulum of skeletal muscle. Anesthesiology. 1999 (im Druck)
167. Steinfath M, Singh S, Scholz J, Becker K, Lenzen C, Wappler F, Köchling A, Roewer N, Schulte am Esch J: C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible Io malignant hyperthermia and the relationship to in vitro contracture response. J. Mol. Med. 1995;73:35-40
168. Sudbrak R, Golla A, Hogan K, Powers P, Gregg R, Du Chesne I, Lehmann-Horn F, Deufel T: Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha1, β1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect Hum. Mol. Genet 1993;2:857-862
169. Sudbrak R, Procaccio V, Klausnitzer M, Curran JL, Curran JL, Monsieurs K, Van Broeckhoven C, Ellis R, Heyetens L, Harlung EJ, Kozak-Ribbens G, Heilinger D, Weissenbach J, Lehmann-Horn F, Mueller CR, Deufel T, Stewart AD, Lunardi J: Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am. J. Hum. Genet. 1995;56:684-691
170. Tegazzin V, Scutari E, Treves S, Zorzato F: Chlorocresol, an additive to commercial succinylcholine, induces contracture of human malignant hyperthermia-susceptible muscle via activation of the ryanodine receptor calcium channel. Anesthesiology. 1996;84:380-385
171. Tonner PH, Scholz J, Richter A, Löscher W, Steinfath M, Wappler F, Wlaz P, Hadjii B, Roewer N, Schulte am Esch J: Alterations of inositol polyphosphates in skeletal muscle during porcine malignant hyperthermia. Br. J. Anaesth. 1995;75:467-471
172. Urwyler A, Hartung E: Die Maligne Hyperthermie. Anaesthesist. 1994;43:557-569
173. Wappler F, Roewer N, Köchling A, Scholz J, Löscher W, Steinfath M, Schulte am Esch J: Effects of the serotonin-2 receptor agonist DOI on skeletal muscle specimen of malignant hyperthermia susceptible patients. Anesthesiology. 1996a;84:1280-1287
174. Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Rumberger E, Löscher W, Schulte am Esch J: Effekte von Serotonin-2-Rezeptoragonisten auf Skelettmuskelpräparate von Patienten mit Disposition zu maligner Hyperthermie. Anaesthesist. 1995;44:238-244
175. Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J: In vitro-diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth. Analg. 1996;82:1230-1236
176. Wappler F, Roewer N, Lenzen C, Scholz J, Steinfath M, Rumberger E, Schulte am Esch J: Hochreines Ryanodin zur in vitro Diagnostik der Malignen Hyperthermie. Anaesth. Intensivmed. Notfallmed. Schmerzther. 1993;28:427-431
177. Wappler F, Roewer N, Lenzen C, Köchling A, Scholz J, Steinfath M, Schulte am Esch J: High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man. Br. J. Anaesth. 1994;72:240-242
178. Wappler F, Scholz J, Fiege M, Kolodzie K, Kudlik C, Weißhorn R, Schulte am Esch J: 4-Chlorom-cresol is a trigger of malignant hyperthermia in susceptible swine. Anesthesiology. 1999;90:1733-1740
179. Wappler F, Scholz J, Köchling A, Steinfath M, Krause T, Schulte am Esch J: Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia. Br. J. Anaesth. 1997;78:541-547
180. Wappler F, Scholz J, von Richthofen V, Fiege M, Steinfath M, Schulte am Esch J: 4-Chloro-m-Cresol induziert Kontrakturen an Skelettmuskelpräparaten von Patienten mit Disposition zu maligner Hyperthermie. Anaesthesiol. Intensivmed. Notfallmed. Schmerzther. 1997;32:541-548
181. Wedel DJ, Gammel SA, Milde JH, Iaizzo PA: Delayed onset of malignant hyperthermia induced by isoflurane and desflurane compared with halothane in susceptible swine. Anesthesiology. 1993;78:1138-1144
182. Wedel DJ, Iaizzo PA, Milde JH: Desflurane is a trigger of malignant hyperthermia in susceptible swine. Anesthesiology. 1991;74:508-512
183. Wedel DJ, Nelson TE: Malignant hyperthermia - diagnostic dilemma: false-negative contracture responses with halothane and caffeine alone. Anesth. Analg. 1994;78:787-792
184. Weingarten AE, Korsh JI, Neumann GG, Stern SB: Postpartum uterine atony after intravenous dantrolene. Anesth. Analg. 1987;66:269
185. Wingard DW: Malignant hyperthermia: a human stress syndrome? Lancet. 1974;II:1450-1451
186. Wollinsky KH, Weiß C, Gelowicz-Maurer M, Geiger P, Mehrkens HH, Naumann T: Präoperative Risikoerfassung bei Kindern mit Muskeldystrophie Typ Duchenne und ihre Relevanz für die Anästhesie sowie den intra- und postoperativen Verlauf. Med. Klinik. 1996;91:34-37
187. Zhang Y, Chen HS, Khanna VK, De Leon S, Phillips MS, Schappert K, Britt BA, MacLennan DH: A mutation in the human ryanodine receptor gene associated with central core disease. Nature Genet. 1993;5:46-50
188. Zorzato F, Fujii J, Otsu K, Phillips MS, Green NM, Lai FA, Meissner G, MacLennan DH: Molecular cloning of cDNA encoding human and rabbit forms of the Ca2 + release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 1990;265:2244-2256